Matko Kalac

机构：Pfizer (United States), The Fertilizer Institute · ORCID：0000-0003-1238-0760

发表论文 120 篇 · 总被引 960 次 · h-index 15

代表论文

• Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial (2025 · The Lancet · 被引 44)
• Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (2025 · New England Journal of Medicine · 被引 42)
• Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial (2025 · The Lancet · 被引 32)
• ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). (2025 · Journal of Clinical Oncology · 被引 9)
• ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients (2026 · European Urology · 被引 7)
• Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age (2025 · European Journal of Cancer · 被引 3)